Alternatives to LiveDesign

Advanced molecular modeling can transform drug discovery and materials research. Our physics-based computational platform combines differentiated solutions for predictive modelling, data analytics, collaboration, and collaboration to allow rapid exploration of chemical space. Our platform is used by industry leaders around the world for drug discovery and materials science in fields such as aerospace, energy, semiconductors and electronics displays. The platform powers our drug discovery efforts, from target identification through hit discovery to lead optimization. It also powers our research collaborations to create novel medicines for critical public healthcare needs. Our team includes more than 150 Ph.D. scientists. This allows us to invest heavily in R&D.

3decision®, a cloud-based repository of protein structures, is designed to manage structural data and perform advanced analytics. This allows small molecule and biologicals discovery teams the ability to accelerate structure-based drugs design. It centralizes, standardizes, and integrates experimental and in silico protein structures derived from public sources such as RCSB PDB, AlphaFoldDB as well as proprietary information, including formats like PDBx/mmCIF, and ModelCIF. This allows for easy access to X-Rays, NMRs, cryo-EMs, and modeled protein structures. It also fosters collaboration and enhances research efforts. 3decision®, beyond storage, enriches entries by adding metadata and sequence data, including annotations of antibodies, binding site details, and protein-ligand interaction. Advanced analytical tools can identify druggable site, assess off-target risk, and enable binding sites comparisons. They transform vast structural data into actionable information. Cloud-based platform allows for collaboration between research teams.

VeraChem LLC was established in 2000 to advance computer-aided drug discovery. These methods are implemented in high-performance software and provide comprehensive support to users. This is a key strategy of VeraChem LLC for product development. Current VeraChem software capabilities include host-guest and protein-ligand binding affinity prediction, fast calculation and computation of partial atomic charges for druglike compounds, computation and force of energies and forces using all the most commonly used empirical force field, automatic generation and generation of alternate resonance forms for drug-like substances, conformational search using the powerful Tork algorithm and automatic detection and removal of topological and 3D-molecular symmetries. VeraChem's software packages were built from a modular code base.

We combine clinical and experimental data with machine learning to improve precision medicine and navigate human disease biology. Contingent AI™, a patent-pending technology, understands data relationships to provide sophisticated insights. We tackle data bias by iterating upon machine learning models that are based on decisions made during the feature engineering and pre-processing stages. We use zebrafish, cell, and other phenotypic animals models to validate in-silico predictions in in vivo experiments. We also genetically modify them in vitro to improve translation. We quickly incorporate new data into machine learning models by using active learning and computer vision on validated models of cardiac, central nervous system, and rare disorders.

Makya is a user-friendly SaaS-based platform for AI-driven drug design focusing on Multi-Parametric Optimization. It allows the design of novel compounds that are easy to make in accordance with a multiobjective blueprint at unprecedented speeds, performance and diversity. Makya has multiple generative algorithms that cover different use cases, from hit discovery to lead optimizing: fine-tuning to find optimal solutions in your chemical space according to your project blueprint; novelty to find new ideas of high novelty for rescaffolding/hit discoveries; forward to design a focused collection of compounds easily accessible using commercial starting materials. The new Makya 3D Module enhances the user-experience and scientific utility of Makya. Makya 3D offers a wide range of 3D modeling capabilities in both ligand and structure-based pipelines. You can now use these 3D scores to guide generation natively within Makya.

Eidogen-Sertanty’s Target Informatics platform (TIP), is the first global structural informatics system. It enables researchers to examine the druggable genome from an structural perspective. TIP increases the rapidly expanding body experimental protein structure information and transforms structure based drug discovery from an inefficient, data-scarce discipline to a high-throughput science with rich data. TIP is a tool that bridges the knowledge gap between bioinformatics (bioinformatics) and cheminformatics. It provides drug discovery researchers with a knowledge bank of information that is both unique and highly complementary to existing bio- and cheminformatics platform information. TIP's seamless integration between structural data management technology and unique target-to-lead analysis capabilities enhances every stage of the discovery pipeline.

A series of carefully planned experiments can help you discover biological biomarkers, uncover disease mechanisms, find new drugs, or identify protein levels changes. It's easy to unlock the power of MS/Proteomics. This allows you to focus on the biological complexity and get closer to the moment for discovery. Our automated, repeatable workflow makes it easier to start experiments and reduce turnaround times. This gives you the flexibility and control to make decisions and act on them immediately. Our proteomics data processing workflow allows you to concentrate on biological insights and human to human collaboration. It is built to scale repeatedly. We have made repetitive and heavy processing easy to use the cloud, making it a seamless and enjoyable experience. Intelligent Proteomics seamlessly integrates complex moving parts to allow larger experiments to be processed, analyzed, and reported with ease.

BIOiSIMTM, a revolutionary 'virtual drug engine', is the first-in-class tool that allows drug developers to narrow down the number drugs that have potential value in treating or curing specific diseases or illnesses. We offer a variety of translational-based solutions that can be customized for your clinical and pre-clinical programs. All of these solutions are based on our BIOiSIMTM platform, which is a proven and validated platform for small molecules, large molecule, and viruses. Our models are built using data from thousands upon thousands of compounds across seven species, which gives them a robustness that is rare in the industry. The platform is focused on human outcomes and has at its core a translatability tool that transforms insights across species. The BIOiSIMTM platform is available before preclinical animal trials begin, which allows for earlier insights and saves on expensive outsourced experimentation.

Genedata Biologics®, streamlines the discovery of biotherapeutics. This includes bispecifics and ADCs as well as TCRs, CARs-Ts, CARs-Ts, CARs, and AAVs. It integrates all discovery workflows, making it the most popular platform in the industry. This allows you to focus on innovation and is the most widely used. A first-in-class platform that digitalizes biotherapeutic discovery accelerates research. The platform simplifies complex R&D processes by allowing for the creation, tracking, testing, and evaluation of novel biotherapeutics drugs. It can work with any format: antibodies, bi- and multi-specifics as well as ADCs, novel scaffolds, therapeutic proteins, and engineered therapeutic cell line such CAR-T cells and TCRs. Genedata Biologics acts as a central data backbone that integrates all R&D processes. This includes library design, immunizations, selections, panning, molecular Biology, screening, protein engineering and expression, as well as candidate development and manufacturability assessment.

Artificial Intelligence and RNA sequencing (RNA–seq data) are both a necessity and a way to develop therapeutics that target splicing mistakes. Machine learning allows us to quickly identify new splicing mistakes and design therapeutic compounds to correct them. SpliceCore, our AI platform for RNA therapeutics research, is what we call SpliceCore. This technology platform was specifically designed for the analysis and interpretation of RNA sequencing data. It can identify, validate and test hypothetical drug targets quicker than traditional methods. Our proprietary database of over 5 million potential RNA-splicing errors is the heart of SpliceCore. It is the world's largest database of splicing mistakes and is used to test all RNA sequencing data that is submitted for analysis. Scalable cloud computing allows us to process large amounts of RNA sequencing data efficiently at a higher speed and lower cost, thereby exponentially accelerating therapeutic innovation.

AI-powered drug discovery is a proven technology. Cerella extracts hidden insights from your drug discovery data to reveal the best compounds and most valuable experiment for your project. It can make confident predictions by accurately filling in the missing values. This is especially useful for expensive downstream experiments, which are impossible to predict using other methods. This allows you to do more with sparse and limited data sets.

StarDrop™, a comprehensive suite of integrated software, delivers the best in silico technology within a highly visual interface. StarDrop™, which allows seamless flow between the latest data, predictive modeling, and decision-making regarding the next round or synthesis, improves the speed, efficiency and productivity of the discovery process. A balance of different properties is essential for successful compounds. StarDrop™, which guides you through the multi-parameter optimization challenge, helps you target compounds with the highest chance of success. It also saves you time and resources by allowing you to synthesize fewer compounds and test them less often.

CDD Vault allows you to intuitively organize chemical structures, biological study data, as well as collaborate with external or internal partners via a simple web interface. Start a free trial to see how easy it can be to manage drug discovery data. Tailored for You Affordable Scales with your project team Activity & Registration * Electronic Lab Notebook * Visualization * Inventory * APIs

Our AI engine transforms drug discovery. Our discoveries help create better medicines faster. Our AI-enabled discovery portfolio is co-owned and owned by prominent investors. Atomwise developed a machine-learning-based discovery engine that combines the power of convolutional neural networks with massive chemical libraries to discover new small-molecule medicines. People are the key to redefining drug discovery using AI. We are committed to creating the best AI platform possible and using it to transform small-molecule drug discovery. To help drug developers achieve their goals, we have to tackle the most difficult and seemingly impossible targets. We also need to streamline the drug discovery process in order to make it more efficient. The ability to screen trillions of compounds in silica increases the chance of success. Demonstrates exceptional model accuracy, surpassing the challenge of false negatives.

The biopharmaceutical market is complex today. There are growing demands for better specificity and safety, new treatment classes, and more complex mechanisms of disease. To keep up with this complexity, we need to have a better understanding of therapeutic behavior. Simulation and modeling provide unique opportunities to explore biological and physical processes down to the atomic levels. This can be used to guide physical experimentation and accelerate the discovery and development process. BIOVIA Discovery Studio brings together more than 30 years of peer reviewed research and world-class in-silico techniques like molecular mechanics and free energy calculations. It also allows for biotherapeutics developmentability and other related topics into one environment. It gives researchers a complete toolkit to explore the nuances in protein chemistry and to catalyze the discovery of small and big molecule therapeutics, from Target ID to Lead Optimizement.

DNAnexus Apollo™, accelerates precision drug discovery through collaboration that draws critical insights from omics data. Precision drug discovery requires the collection and analysis of large volumes of clinical and omics data. These data sets are extremely rich, but many legacy and home-grown informatics tools cannot handle their complexity and size. Silos, insufficient collaboration tools, and complex regulatory and security requirements can all hinder precision medicine programs. DNAnexus Apollo™, which supports precision drug discovery programs, empowers scientists and clinicians to analyze and explore omics and clinical data in a single environment built on a robust and scalable cloud platform. Apollo allows them to share data, tools and analyses securely with peers and colleagues from all over the world, regardless of whether they are on another floor or another continent.

Site-Identification by Ligand Competitive Saturation generates 3D maps (FragMaps), showing interaction patterns for chemical functional group with your target molecule. Site-Identification through Ligand Competitive Saturation generates 3D maps, (FragMaps), of interaction patterns for chemical functions groups with your target molecule. SILCS reveals the intricacies and provides tools to optimize ligand scaffolds through qualitative and quantitative binding pocket insights. This allows for faster and more effective drug design. SILCS employs multiple small molecule probes that have different functional groups and explicit solvent modeling to perform protein target mapping. Visualize positive interactions with the target macromolecule. Get insights to design better binding agents with the best functional groups.

Rare diseases are often poorly understood and only a small amount of information is available to support drug discovery programs. Healnet, an AI platform that analyzes millions of data points related to drug and disease, helps overcome these challenges. It identifies novel connections that could lead to new treatment options. We can simultaneously run multiple stages at scale by applying frontier technologies throughout the discovery and development process. It's a simple model that can be used by almost all pharmaceutical companies. One disease, one target and one drug. The next generation in drug discovery is AI-powered and parallel. The key three paradigms of drug discovery are combined.

Aurora uses quantum mechanics, thermodynamics and an advanced continuous-water model for solvation effects in order to calculate ligand binding affinities. This approach is significantly different from the binding affinity predictions that are often based on scoring functions. Aurora algorithms are able to produce more precise and reliable binding free energies values by including the entropy as well as the aqueous electrostatic contribution directly into the calculations. The binding free energy is the measure of interaction between a ligand and a protein. The free energy (F), which is a thermodynamic quantity directly related to the experimentally measurable value for inhibition constant (IC50), and depends on the statistical properties of interacting molecules as well as electrostatic, quantum, and aqueous solver forces, is a thermodynamic quantity. Two major contributors to F's non-additivity are 1) the electrostatic and the solvation energy, and 2) the entropy.

BioNeMo, an AI-powered cloud service for drug discovery and framework, is built on NVIDIA NeMo Megatron. It is used to train and deploy large biomolecular Transformer AI models at supercomputing scale. The service provides pre-trained large language models (LLMs), native support for common file types for proteins, DNA, and chemistry, as well as data loaders for SMILES molecular structures and FASTA amino acid and nucleotide sequencings. You can also download the BioNeMo framework to run on your own infrastructure. ESM-1, which is based on Meta AI’s state-of the-art ESM-1b and ProtT5 respectively, are transformer-based protein-language models that can be used for learning embeddings for tasks such as property prediction and protein structure. BioNeMo will offer OpenFold, a deep-learning model for 3D structure prediction and novel protein sequences.

NoviSight 3D Cell Analysis Software advances your discovery by providing statistical information for spheroids, and other 3D objects in microplate based experiments. It allows you to quantify cell activity in three dimensions, capture rare events more easily, increase detection sensitivity, and obtain accurate cell counts. NoviSight software has a simple user interface that allows you to perform analysis, recognition, and statistical analyses. NoviSight software's True 3D technology allows you to easily check the morphology and size of your samples. To speed up your research, measure a variety of cell nuclei parameters such as volume and sphericity. You can also analyze 3D cell models that are physiologically relevant to your work. The software can be used to analyze objects of interest and provide spatiotemporal and morphological information in 3D space. You can detect objects from whole structures to subcellular details and analyze changes in spheroids.

Amazon Neptune is a fully managed graph database service that allows you to quickly and reliably build applications that can work with highly connected data sets. Amazon Neptune's core is a purpose-built graph database engine that can store billions of relationships and query the graph with only milliseconds latency. Amazon Neptune supports the popular graph models Property Graph, W3C's RDF, as well as their respective query languages Apache TinkerPop Gremlin, SPARQL. This allows you to quickly build queries that efficiently navigate large datasets. Neptune supports graph use cases like recommendation engines, fraud detection and knowledge graphs. It also powers network security and drug discovery.

Use AI to accelerate the journey from bench-research and laboratory insights to life-changing therapies. Reduce your reading time to minutes and gain up to 90% more research productivity. With a high-precision and high-accuracy research, you can cut through the noise to navigate the ever-growing amount of scientific literature. Save time, reduce bias, and increase the odds of discovering novel things. Explore disease biology in depth and discover advanced targets. Causaly’s high-precision graph of knowledge consolidates evidence from millions publications, allowing for unbiased, deep scientific exploration. You can navigate cause-and effect relationships in biology without being an expert. Discover hidden connections by viewing all scientific documents. Causaly’s powerful AI machine is able to read millions of published biomedical publications in order to support better research and decision-making.

These intricate, complex machines are proteins. They are the building blocks of all biological processes, not only in your body, but in every living being. They are the building blocks of all life. There are currently around 100 million distinct proteins. Many more are discovered every year. Each protein has a unique 3D shape, which determines how it functions and what it does. It is expensive and time-consuming to determine the exact structure of each protein. This means that we only have a small number of proteins in our database. This gap is rapidly growing and we need to be able to predict the structure of millions unknown proteins. This could help us not only tackle disease but also help us find new medicines more quickly. It may also help us unlock the mysteries of life.

Discngine Assay, a laboratory informatics tool, integrates all phases of plate-based tests into a coherent, compliant and efficient workflow. It is an essential tool for research labs that screen. It allows scientists to streamline their entire High Throughput screening workflow, from sample analysis and assay data storage to data warehousing to liquid handling equipment qualification. Discngine Assay's intuitive interface and robust API integrate seamlessly with Lab equipments, existing IT environments, and ensure efficient data capture and analysis. It is designed to accelerate the discovery of new molecules, while also addressing the needs of the pharmaceutical, biotech and CRO industries. This will enhance collaboration and drive innovation in life sciences research.

ChemDraw®, solutions have been able to provide powerful capabilities and integrations that allow you to quickly transform ideas and drawings into publications you are proud of. ChemOffice+ Cloud is a chemistry communication suite that transforms chemical drawings into chemical knowledge. It facilitates the management, reporting, and presentation of your Chemistry research. ChemOffice+ Cloud is a robust and comprehensive suite that was designed to simplify, facilitate, accelerate, and accelerate chemistry communication. The cloud-native ChemDraw Professional chemistry communication suite adds a powerful set to scientific research by adding a powerful set to the foundations. ChemOffice+ Cloud makes it much easier to create reports to communicate chemical research. Chemists can use ChemOffice+ cloud to create PowerPoint slides and manuscripts that are ready for presentation.

We are a biotechnology company in clinical stage. We decode biology by integrating technological innovations across biology and chemistry to industrialize drug discovery. CRISPR genome editing and synthetic Biology allow for greater control over biology. Advanced robotics allows for reliable automation of complex laboratory research on an unprecedented scale. Neural network architectures allow for iterative analysis and inference from large, complex, in-house data sets. Cloud solutions increase the flexibility of high-performance computation. To build a next-generation biopharmaceutical business, we are using new technology to create virtuous learning cycles around datasets. A synchronized combination hardware, software, and data that is used to industrialize drug discovery. Redefining the traditional drug discovery process. One of the most extensive, broadest, and deepest pipelines in any technology-enabled drug company.

Our reputation as thought leaders in the areas of ADMET property prediction, physiologically-based pharmacokinetics (PBPK) modeling, pharmacometrics, and quantitative systems pharmacology/toxicology is earned through the success our clients have found through their relationship with us. With over 20 years of experience, we have the ability to translate science into software that is easy to use. We also provide expert consulting support for drug discovery, clinical research, and regulatory submissions.

Scitara DLX™ provides a fast connectivity infrastructure for any instrument used in life science laboratories. It is fully compliant and auditable, and can be accessed from any cloud-based platform. Scitara™, a universal digital data network, connects all instruments, resources, apps, and software within the laboratory. The cloud-based platform, which is fully auditable, connects all data sources in the lab, allowing data to flow freely across multiple endpoints. Scientists can now spend their time on scientific research and not waste it trying to solve data problems. DLX corrects and curates flight data to support the creation of precise, structured data models that feed AI/ML systems. This supports a successful digital transformation strategy for the pharma and biopharma sectors. The ability to access scientific data allows for faster decision-making and drug discovery, which helps bring drugs to market quicker.

Kanteron Platform ingested digital pathology slides, medical images, and patient data from modalities and sequencers. It then provided a complete data toolkit for all hospital network teams. Precision Medicine at the point-of-care: Pharmacogenomics is used to prevent adverse medication events. It also incorporates data sources that have drug-gene interactions that were not previously available in easily accessible formats (e.g. Tables in a PDF document) and implementing the major Pharmacogenomic Databases (like PharmGKB or DGIdb, OpenTargets ...). This allows the user to refine their query to specific gene families, types, interactions, etc. Flexible AI allows you to choose the data set that is most appropriate for your use case and then apply it to your relevant medical images.

AutoDock is a set of automated docking tools. It predicts how small molecules, such sub- or drug candidates, will bind to a receptor with a known 3D structure. It has been improved over the years to add new functionalities and multiple engines were developed. AutoDock 4 is the current version, and AutoDock Vina is the latest. AutoDock-GPU is an accelerated version that runs hundreds of times faster than the original single CPU docking code. AutoDock 4 is actually composed of two main programs. Autodock docks the ligand to a list of grids that describe the target protein. Autogrid pre-calculates the grids. The atomic affinity grids can also be visualized. This can be used to help organic synthetic chemists create better binders.

InSilicoTrials.com, a web-based platform that allows users to create and simulate computational models and simulations. There are many easy-to-use tools in silico. The platform is primarily for users in the medical device and pharmaceutical industries. In silico tools for medical devices allow computational testing in different biomedical areas such as radiology, orthopedics, and cardiovascular during product development, validation, and design. The platform offers access to in-silico tools for the pharmaceutical industry, which can be used at all stages of drug discovery and development. It also covers a variety of therapeutic areas. The only cloud-platform built on crowdscience makes it easy to access validated models and reduce your R&D expenses. There is a growing list of models that can be used on a pay-per-use basis.

BC platforms uses the latest science, unique technology capabilities and strategic partnerships to accomplish our mission of revolutionizing drug discovery, personalizing care, and transforming medicine. Modular, flexible platform that integrates healthcare data. Open analytics framework seamlessly combines the most innovative methods, technology developments and analytics in one platform. Superior security: ISO 27001 certified and GDPR and HIPAA compliant. A complete product portfolio allows modern healthcare systems to fully embrace personalized medicine. Scalable deployments allow for a robust start and large-scale healthcare operation. Our unique toolbox enables faster translation of research insights into clinical practice. Our unique toolbox helps reduce risk, increase your pipeline value, and advance enterprise data strategy. We remove the barriers to data access and enable rapid insight generation.

ArgusLab is a program that allows you to molecular model, graphically, and design drugs for Windows operating systems. Although it is becoming a little outdated, it remains very popular. There have been more than 20,000 downloads to date. ArgusLab can be downloaded for free. You don't have to sign anything. If you're teaching a class in which ArgusLab might be useful, you can print as many copies as necessary. You cannot redistribute ArgusLab to other websites or sources. You may link to this website on your own websites, however. ArgusLab is being port to the iPad in a low-key effort. I have also worked with Qt cross-platform development environment to support Mac, Linux, and PC.

Chemia is a browser-based & cloud-ready ELN platform. Chemia was designed, developed and architected by scientists. It is a platform that allows you to manage, assign, monitor, and track all R&D activities. It allows you to automate your R&D setup and makes it paperless. It saves time (approx. It saves time (approx. 1 hour per scientist) through Cross-functional collaboration. This makes it audit-ready and helps you manage data effectively. Fast retrieval, search, comparative studies, and reconfigurability allow for faster and more appropriate decisions. A system for managing inventory and scheduling information for chemicals and equipment within a laboratory. A system that tracks equipment usage, maintenance logs, and calibration logs. This is essential for efficient lab management and effective working. A system that provides the protocol, and ensures compliance.

Automated surveillance of any source of data, fully integrated with a GVP IX-compliant signal management platform. GVP-IX compliant signal-management platform integrated into Evidex and ready-to-use off-the-shelf. Modernize and audit-proof all your management processes without the need to switch between platforms or services. Your safety data is worth more than you think. Automating signal detection and management allows you to focus on your organization's value, not just regulatory requirements. Safety signals can be identified from traditional sources such as ICSR databases, FDA Adverse Events Reporting System (FAERS), VigiBase, and clinical trial data. Incorporate new data sources like claims, EHR, or other unstructured data. These data sources can be combined seamlessly to improve signaling algorithms, increase validations and assessment efficiency, and provide faster answers for drug safety questions.

The process of bringing a new drug to market, from the initial step to the final market introduction can be time-consuming, expensive, and highly regulated. It can take up to a decade. Final success depends on early access to accurate analytical results that are fast enough to make the right decisions during development and minimize late attrition. Today's drug development relies heavily on a rational approach. Typically, identifying the biological target is the first step. To identify the most promising candidates, it is necessary to have a deep understanding about their properties. Finding the most promising lead molecules can be a daunting task once a biological target is established. Lead discovery is typically the identification of potential drug candidates, either small organic molecules or biologic assembly with therapeutic potential.

Genedata Imagence®, allows you to train a deep neural net to classify cellular characteristics in HCS images. This will give you objective, high-quality results. It automates your analysis to allow assay biologists to harness the power of deep learning algorithms. Genedata Imagence allows biologists to immediately and directly analyze HCS imaging data with sophisticated deep learning techniques using no specialized algorithmic knowledge. Don't hide your analysis behind abstract lines of code. Genedata Imagence's intuitive interface makes it easy to QC and explore data at every stage.

Predict absorption distribution metabolism and excretion properties from chemical structure. This collection of high-quality calculations for pharmacokinetic properties can be used to support high-throughput screening of libraries. It also provides insight into pharmacological effects and can help ensure that products are safe for humans.

Global biopharmaceutical drug patents and generic entry business intelligence. Anticipate future budget needs and proactively find generic sources. Examine past successes of patent challengers to identify research paths for competitors. Inform portfolio management decisions on future drug development. Predict brand drug patent expiration, identify generic supplier, and prevent overstocking of branded drugs. Get formulation and manufacturing information. Identify final formulators, repackagers and relabelled.

Clara's domain specific tools, AI pretrained models, accelerated applications, and accelerated AI applications are enabling AI advances in many fields, including medical device, imaging, drug discovery and genomics. Holoscan allows you to explore the entire pipeline of medical device deployment and development. With the NVIDIA IGX Developer Kits, you can build containerized AI apps using the Holoscan SDK. The NVIDIA IGX SDK includes pre-trained AI model, healthcare-specific acceleration libraries and reference applications for medical devices.

AIDDISON™, a drug discovery software, combines the power and efficiency of artificial intelligence (AI), computer-aided design (CADD), and machine learning (ML) to provide a valuable toolkit that can be used for medicinal chemistry. It is a unified platform that integrates all aspects of virtual screening, including ligand-based design and structure-based design. It also supports methods for in silico lead optimization and discovery.

Preclinical information is found in many laboratories. It can be stored in multiple systems within the laboratory and with several external partners. Team members are unable to have clear and informed decisions without a unified solution because they lack transparency in core business data. Pristima, a fully integrated digital laboratory execution platform, features intelligent workflows, task automation, and data and information management throughout the entire preclinical process. Xybion's preclinical platform provides a central data repository as well as a standard archive platform. This platform can help you increase productivity and lower costs. With complete transparency across all platforms, gain visibility into the information that is there and take actions based on your current business needs. Effective data management can reduce the time it takes to submit final SENDs from end-of-study.

Dotmatics is the global leader in R&D scientific software that connects science, data, and decision-making. More than 2 million scientists and 10,000 customers trust Dotmatics to accelerate research and help make the world a healthier, cleaner, and safer place to live.

Our immunotherapy approach starts with our understanding of antigens. We also know which neoantigens will be present on cells by Human leukocyte antigen molecules. This will allow us to identify the ones that will be transcribed and translated. Gritstone EDGETM is our machine-learning-based platform that enables us to accomplish this. It is difficult to develop cancer immunotherapies that include tumor specific neoantigens. Tumors can have hundreds of mutations. However, only a small number of these mutations result in true tumor-specific antigens. We used EDGE's new integrated neural network architecture to train it with millions of data points from hundreds tumor and normal tissue samples taken from patients of different ancestries.

Cortellis™, a suite of life science intelligence software solutions, reveals hidden insights in data. This allows you to make better informed decisions throughout the R&D process. We have taken out the tedious work of finding, integrating and analysing data so that you can concentrate on the crucial decisions required to bring your products to market quicker. Cortellis provides unique data analysis that is rich in domain knowledge, industry insight, and therapeutic expertise. This allows you to unlock hidden insights that will allow you to make data-driven decisions that drive innovation. With the most comprehensive and deepest intelligence, you can get precise and actionable answers to specific questions throughout the R&D process. Cortellis is an indispensable part your daily work flow.

A platform that connects scientific reasoning, compound design, computational resources, and other relevant information. The Design Hub by Chemaxon for medicinal chemistry, from analysis to prioritization. One platform to design compounds and manage ideas. One platform that links scientific rationale, compound design, computational resources, and other information. You can switch from PowerPoint files to graphical or chemically searchable hypotheses, which are integral parts of compound design. You can easily work in a rich visual environment with your trusted physchem properties, computational models or novelty issues. This secure online service allows you to involve your CROs in compound progression. Analyze the evidence from biological assays and experimental structural information to extract SAR and create new hypotheses for each optimization iteration. Your scientific hypotheses can be stored in a "designer’s ELN" (chemically-aware drawing canvases).

FCS Express™ gets you from raw data to easily-understandable, beautifully formatted, presentation-ready results more easily and in less time than any other flow cytometry software. You've probably had to copy and paste data tables into another software to make your data more understandable and visually appealing. You've probably had to manage your data in multiple software packages, such as Microsoft Excel™, GraphPad Prism™, or Microsoft Excel™. It was difficult to find everything you needed in one program. Learning flow cytometry software shouldn't be a barrier to getting the best results from your data. FCS Express is designed to look and feel like familiar Microsoft Office™, so you can already be an expert before you even start.

Chemical Computing Group (CCG), has a strong reputation in collaborative scientific support. Our team of PhD-level scientists has offices in North America and Europe. They work closely with clients to provide support, hands-on training, and scientific advice on a wide variety of projects. CCG continues to develop new technologies through its team of scientists, mathematicians and software engineers as well as scientific collaborations with customers.

Calculate Abraham Solvation Parameters, and other solvation-related properties for solutes, directly from the chemical structure